Latest data suggests Sareums SRA737 Chk1 inhibitor has potential in ovarian cancer

Latest data suggests Sareum’s SRA737 Chk1 inhibitor has potential in ovarian cancer

Data presented at a cancer convention in Dublin suggested SRA737 showed “promising efficacy” in pre-clinical models of high-grade serous ovarian cancer

More From BioPortfolio on "Latest data suggests Sareum’s SRA737 Chk1 inhibitor has potential in ovarian cancer"